Equities

Nuwellis Inc

Nuwellis Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)1.93
  • Today's Change0.00 / 0.00%
  • Shares traded587.18k
  • 1 Year change-90.66%
  • Beta0.3984
Data delayed at least 15 minutes, as of Nov 13 2024 20:33 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nuwellis, Inc. is a medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.

  • Revenue in USD (TTM)9.01m
  • Net income in USD-22.81m
  • Incorporated2002
  • Employees59.00
  • Location
    Nuwellis Inc12988 Valley View RdEDEN PRAIRIE 55344-3657United StatesUSA
  • Phone+1 (952) 345-4200
  • Fax+1 (302) 636-5454
  • Websitehttps://www.nuwellis.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Leafbuyer Technologies Inc5.43m-959.15k2.10m14.00------0.3872-0.0096-0.00960.0545-0.01793.64--41.85387,721.40-64.23-62.47----35.2333.53-17.67-62.40---6.34----33.7235.17-161.23------
Tivic Health Systems Inc1.11m-6.75m2.39m9.00--0.5704--2.15-4.33-4.330.54690.67790.23730.915676.76123,666.70-143.94---176.98--27.85---606.47--6.59--0.00---36.09--18.34------
Vycor Medical Inc1.36m-506.30k2.43m8.00------1.79-0.0155-0.01560.0417-0.10811.430.66945.08170,011.30-19.13-47.86----89.2389.60-13.38-35.420.0987-0.8001----19.43-0.654246.49---31.77--
HeartSciences Inc18.60k-7.29m2.58m15.00--0.4308--138.47-5.65-5.650.00116.550.00350.0092--1,240.00-135.14---193.38--67.31---39,193.76--4.02-20.720.0777--261.17---3.95------
NanoVibronix Inc3.37m-2.82m2.66m10.00--0.6958--0.7899-1.32-1.321.501.020.70810.43112.05337,300.00-59.12-116.16-122.41-169.3664.5750.47-83.49-570.471.16-14.770.00--203.5948.3331.88---34.02--
Avinger Inc7.43m-15.34m2.69m68.00--0.2076--0.3615-12.13-12.135.834.050.4341.238.03109,250.00-113.20-70.93-1,387.68-131.5719.9630.87-260.86-208.911.20-11.660.3428---7.51-0.673632.76---24.21--
Venus Concept Inc69.81m-49.93m2.70m304.00--0.7298--0.0387-8.38-8.3811.920.51030.7511.032.25229,634.90-53.53-32.71-82.19-44.0168.3968.16-71.28-48.501.30-2.750.9133---23.2628.3114.76---35.08--
ReShape Lifesciences Inc8.05m-9.02m2.72m31.00--0.8947--0.3375-74.86-74.8627.645.990.8820.80354.79259,548.40-98.88-136.06-169.55-194.3267.4756.30-112.11-408.360.8875--0.00---22.79-0.947475.36---49.29--
NAYA Biosciences Inc5.77m-7.08m3.28m25.00------0.568-3.24-3.242.440.35290.467712.0034.74230,781.20-57.44-94.63-116.03-151.4544.8974.91-122.80-343.110.2686-4.750.6588--267.3843.6226.24--87.09--
Nuwellis Inc9.01m-22.81m3.60m59.00------0.3997-181.60-181.6048.48-13.250.82921.527.30152,779.70-192.57-98.07-301.19-122.4860.2855.22-232.24-230.510.7119-1.52----3.7612.14-55.78--4.61--
Reflect Scientific Inc1.73m-53.09k4.03m7.00--2.0452.272.32-0.0006-0.00060.02030.0230.71970.846317.05247,638.60-2.2011.10-2.5913.2158.1962.48-3.0610.005.68--0.00---47.09-6.99-613.46------
AccuStem Sciences Inc0.00-1.65m4.76m3.00---------0.1454-0.14540.00-0.25420.00----0.00-551.46--------------------------45.26------
Sharps Technology Inc0.00-8.21m4.91m3.00--0.4915-----10.88-10.880.005.550.00-------75.56---100.97----------0.6446--0.00-------112.12------
Optimus Healthcare Services Inc1.89m-7.16m4.92m12.00------2.61-0.1744-0.17440.0454-0.18891.26--3.67157,291.70-477.28------85.93---379.51-----5.42----22.88---3.51------
Encision Inc6.56m-529.29k4.99m22.00--2.68--0.7599-0.045-0.0450.5560.15661.702.107.59298,337.30-13.69-3.03-19.50-4.1349.0051.25-8.06-1.891.01-8.890.1761---10.38-5.64-113.55---9.54--
Data as of Nov 13 2024. Currency figures normalised to Nuwellis Inc's reporting currency: US Dollar USD

Institutional shareholders

2.24%Per cent of shares held by top holders
HolderShares% Held
S.H.N. Financial Investments Ltd.as of 26 Apr 202429.76k1.59%
Citadel Securities LLCas of 30 Jun 202411.34k0.61%
Tower Research Capital LLCas of 30 Jun 2024676.000.04%
Wells Fargo Securities LLCas of 30 Jun 2024100.000.01%
Bank of America, NA (Private Banking)as of 30 Jun 20244.000.00%
Qube Research & Technologies Ltd.as of 30 Jun 20242.000.00%
JPMorgan Securities LLC (Investment Management)as of 30 Sep 20241.000.00%
Two Sigma Securities LLCas of 30 Jun 20240.000.00%
HRT Financial LP (US)as of 30 Jun 20240.000.00%
Virtu Americas LLCas of 30 Jun 20240.000.00%
More ▼
Data from 30 Jun 2024 - 29 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.